重组人 CD19 蛋白 (Site-Specific AF 647-Conjugated, ECD, His Tag)

Recombinant Human CD19 Protein (Site‑Specific AF 647 Conjugation, ECD, His Tag)

Cat No: 11880‑H08W1‑SG｜Official product page:        https://cn.sinobiological.com/recombinant-proteins/human-cd19-11880-h08w1-sg

Specifications

Alternate Names

Background

The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD proteins do not take part in cell signal process but have other functions such as cell adhesion. Cluster of differentiation 19 (CD19) is a member of CD system. CD19 is a cell surface molecule that assembles with the antigen receptor of B‑cells. This results in a descent in the threshold for antigen receptor‑dependent stimulation. A simplified view holds that the ability of B‑cells to respond to the various antigens in a specific and sensitive manner is achieved in the presence of low‑affinity antigen receptors. CD19 primarily acts as a B‑cell co‑receptor in conjunction with CD21 and CD81. The formation of the receptor complex is induced by antigen and CD19, induced by exogenous antigen, has been found cytoplasmic tail phosphorylated and bind to sIg.

北京义翘神州科技股份有限公司作为国家高新技术企业，主要从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务，同时也为制药公司或者生物技术公司提供单克隆抗体候选药物的临床前规模生产服务。义翘神州拥有多项先进的核心技术以及从研发生产到放大生产的技术平台，为重组蛋白或者抗体试剂的高通量、高效率研发生产提供保障，旨在为全球制药企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。 北京义翘神州是入选科技部"现代服务创新发展示范企业"的唯一的一家生物技术企业，是北京市民营企业科技创新百强，获批北京市单克隆抗体技术重点实验室，多次承担国家科技部重大新药创制专项、863科技攻关项目和北京市科委项目。